Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Heerings

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
JMIR Formative Research|November 17, 2021
A Two-Minute Walking Test With a Smartphone App for Persons With Multiple Sclerosis: Validation StudyPim van Oirschot, Marco Heerings, Karine Wendrich, et al.
BMC Research Notes|July 31, 2016
Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year laterPeter Joseph Jongen, Marco Heerings, Rob Ruimschotel, et al.
Health and Quality of Life Outcomes|March 21, 2014
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational studyPeter Joseph Jongen, Rob Ruimschotel, Marco Heerings, et al.
Plos One|October 11, 2019
Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trialPeter Joseph Jongen, Ghislaine A van Mastrigt, Marco Heerings, et al.
Plos One|November 30, 2018
Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international surveyAndrea Giordano, Katrin Liethmann, Sascha Köpke, et al.
Journal of Medical Economics|May 16, 2019
An economic evaluation attached to a single-centre, parallel group, unmasked, randomized controlled trial of a 3-day intensive social cognitive treatment (can do treatment) in patients with relapsing remitting multiple sclerosis and low disabilityGhislaine A van Mastrigt, Silvia M Evers, Marco Heerings, et al.
Clinical Neurology and Neurosurgery|July 25, 2013
Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosisDirk De Ridder, Frank Van Der Aa, Jan Debruyne, et al.
BMC Neurology|May 29, 2016
An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocolPeter Joseph Jongen, Marco Heerings, Rob Ruimschotel, et al.
Journal of Neurology|June 9, 2016
Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapsePeter Joseph Jongen, Ioanna Stavrakaki, Bernard Voet, et al.
Disability and Rehabilitation|November 9, 2019
A Dutch validation study of the Multiple Sclerosis Work Difficulties Questionnaire in relapsing remitting multiple sclerosisElianne van Egmond, Dennis van Gorp, Cynthia Honan, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
JMIR Formative Research|November 17, 2021
A Two-Minute Walking Test With a Smartphone App for Persons With Multiple Sclerosis: Validation StudyPim van Oirschot, Marco Heerings, Karine Wendrich, et al.
BMC Research Notes|July 31, 2016
Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year laterPeter Joseph Jongen, Marco Heerings, Rob Ruimschotel, et al.
Health and Quality of Life Outcomes|March 21, 2014
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational studyPeter Joseph Jongen, Rob Ruimschotel, Marco Heerings, et al.
Plos One|October 11, 2019
Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trialPeter Joseph Jongen, Ghislaine A van Mastrigt, Marco Heerings, et al.
Plos One|November 30, 2018
Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international surveyAndrea Giordano, Katrin Liethmann, Sascha Köpke, et al.
Journal of Medical Economics|May 16, 2019
An economic evaluation attached to a single-centre, parallel group, unmasked, randomized controlled trial of a 3-day intensive social cognitive treatment (can do treatment) in patients with relapsing remitting multiple sclerosis and low disabilityGhislaine A van Mastrigt, Silvia M Evers, Marco Heerings, et al.
Clinical Neurology and Neurosurgery|July 25, 2013
Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosisDirk De Ridder, Frank Van Der Aa, Jan Debruyne, et al.
BMC Neurology|May 29, 2016
An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocolPeter Joseph Jongen, Marco Heerings, Rob Ruimschotel, et al.
Journal of Neurology|June 9, 2016
Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapsePeter Joseph Jongen, Ioanna Stavrakaki, Bernard Voet, et al.
Disability and Rehabilitation|November 9, 2019
A Dutch validation study of the Multiple Sclerosis Work Difficulties Questionnaire in relapsing remitting multiple sclerosisElianne van Egmond, Dennis van Gorp, Cynthia Honan, et al.
Pageof 3